Tonix Pharmaceuticals to Present TNX-1500 Research at American Transplant Congress 2024

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical entity listed on Nasdaq under the ticker TNXP, has announced its participation in the upcoming American Transplant Congress 2024, set to take place from June 1-5 at the Pennsylvania Convention Center in Philadelphia. The company will be presenting two oral presentations and one poster presentation.

The first oral presentation will be delivered by Dr. Kohei Kinoshita from the Center for Transplantation Sciences at Massachusetts General Hospital. The presentation, titled "Combined Blockade of the CD154 and CD28 Co-Stimulation Pathways Attenuates Pathogenic Alloimmunity and Prolongs Survival in Cynomolgus Cardiac Allografts," is scheduled for Tuesday, June 4, 2024, at 9:45 a.m. ET in Room 109-AB, Level 1. The research focuses on the effectiveness of blocking CD154 and CD28 co-stimulation pathways to reduce harmful immune responses and extend the longevity of cardiac allografts.

The second oral presentation, to be given by Dr. Ikechukwu Ileka of Massachusetts General Hospital and Harvard Medical School, is titled "Extended Survival of 9- and 10-Gene-Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade-Based Immunosuppression." This presentation will occur on Tuesday, June 4, 2024, at 10:15 a.m. ET in Room 114, Nutter Theater, Level 1. The study highlights the survival benefits of genetically edited pig heart xenografts when combined with specific immunosuppressive techniques.

Dr. Ileka will also present a poster titled "Experience with a Novel Delayed Immune Tolerance Protocol in Nonhuman Primates Based on Anti-CD154, Anti-CD2, and Anti-CD28." Scheduled for Monday, June 3, 2024, at 9:15 a.m. ET in the Poster Hall, Exhibit Hall A, Level 2, the poster presentation will discuss innovative immune tolerance strategies in nonhuman primates using a combination of antibody treatments.

Tonix Pharmaceuticals is dedicated to the development, licensing, and commercialization of therapeutics aimed at treating and preventing human diseases, particularly focusing on central nervous system (CNS) disorders. The company plans to submit a New Drug Application (NDA) to the FDA for Tonmya1 in the second half of 2024, a product candidate meant for managing fibromyalgia. Tonix is also working on TNX-102 SL for acute stress reaction and fibromyalgia-type Long COVID.

Their CNS portfolio includes TNX-1300, a biologic designed to treat cocaine intoxication, which has received Breakthrough Therapy designation. Additionally, Tonix is developing TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), to prevent organ transplant rejection and treat autoimmune diseases. The company also has product candidates for rare and infectious diseases.

Under its commercial subsidiary, Tonix Medicines, the company markets Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) for acute migraine treatment in adults.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!